Kronos Bio (KRON) said Wednesday that its board has named Deborah Knobelman as president and interim chief executive officer, starting Dec. 3.
Knobelman will succeed Norbert Bischofberger, who will step down Dec. 3 but remain on the board of directors and serve as an advisor, Kronos said.
The company also said it will reduce its workforce by about 83% by the end of year as part of a cost reduction strategy while exploring possible business combinations or sale of preclinical assets.
Kronos Bio shares were rising more than 11% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。